Regeneron Pharmaceuticals REGN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $727.2M-10.1% | $844.6M-8.0% | $1.46B+8.9% | $1.39B-2.8% | $808.7M+12.0% | ||
| $123.2M-2.9% | $145M+14.7% | $136.7M+12.3% | $135.1M+11.9% | $126.9M+11.2% | ||
| $257.4M+0.7% | $249.3M-18.1% | $237M+5.3% | $251.7M+12.8% | $255.7M+11.1% | ||
| -$1.2M+99.8% | —— | —— | —— | -$657.8M-47.2% | ||
| -$26.6M-117% | $0-100% | $82.6M-49.8% | $42.5M-76.6% | $152.3M-2.2% | ||
| $107.7M+150% | $0-100% | $759.2M+291% | $216.4M+5.8% | -$214.1M-294% | ||
| $99.6M+463% | -$3.1M— | —— | -$142.9M-260% | $17.7M-84.9% | ||
| $1.08B+3.2% | $1.17B-7.3% | $1.62B+25.4% | $1.14B+223% | $1.05B-30.9% | ||
| $230.6M+0.6% | $248.7M+24.6% | $201.4M-16.7% | $219M+21.3% | $229.3M+71.2% | ||
| -$428.9M-166% | —— | -$402.9M+29.9% | -$1.09B-96.3% | $647.5M+138% | ||
| $97.8M+4.3% | $92.7M— | $91.2M— | $92.6M— | $93.8M— | ||
| $794.3M-23.7% | $671.7M-31.0% | $664M-9.7% | $1.06B+75.8% | $1.04B+258% | ||
| $163.1M+169% | $503.5M+454% | $40.3M-84.2% | $31.5M-92.8% | $60.6M-91.1% | ||
| $73.2M+1,602% | $519.2M+105% | $3M-97.5% | $5.6M-98.2% | $4.3M-98.7% | ||
| -$802.2M+26.3% | -$780.1M+31.3% | -$717.9M-13.2% | -$1.13B-136% | -$1.09B-2,413% | ||
| -$900K-250% | —— | —— | $400K+233% | $600K+220% | ||
| -$153.1M-125% | $610.6M— | $497.5M— | -$1.08B-58.1% | $604M+572% | ||
| —— | $10.4M-20.9% | $10.4M-20.9% | $10.4M-20.9% | $10.4M-20.9% | ||
| $96M-31.0% | $232.5M-17.0% | $278.6M+65.2% | $135.2M+14.5% | $139.1M-26.9% | ||
| $198.6M+10.6% | —— | $47.9M— | $230.7M-56.2% | $179.5M+130% | ||
| -$55.6M-1,638% | -$136.9M-101% | -$16.3M-156% | $20.9M+597% | -$3.2M-3,100% | ||
| $48.9M+15.9% | $42M-37.7% | $43.3M— | $187.8M+518% | $42.2M+51.3% | ||
| $0+100% | —— | —— | —— | -$10.3M— | ||
| $848.3M+4.0% | $922M-13.3% | $1.42B+35.1% | $925.4M+433% | $815.8M-40.8% | ||
| $848.3M+4.0% | $922M-13.3% | $1.42B+35.1% | $925.4M+433% | $815.8M-40.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Regeneron Pharmaceuticals generate?
- Regeneron Pharmaceuticals (REGN) generated $5.0B in operating cash flow over the trailing twelve months.
- What is Regeneron Pharmaceuticals's free cash flow?
- After $899.7M of capital expenditures, Regeneron Pharmaceuticals's free cash flow was $4.1B over the trailing twelve months, up 32.6% year over year.
- Where does Regeneron Pharmaceuticals's cash flow data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
